Sunday, November 04, 2018 8:10:19 AM
I tapered off of alprazolam a couple of months ago, but I still feel that sleep, tinnitus, and alterations in taste that took place during withdrawal are improving very slowly.
Tremor may also be improving slowly, I'm not sure. The tremor was a side effect of buspirone. It went away after I quit but came back. It may have come back because they put me on alprazolam. I am still taking primidone for the tremor, but thinking of going off of it too...
https://www.mayoclinic.org/drugs-supplements/primidone-oral-route/side-effects/drg-20065638
I am sharing this because I have become acutely aware that doctors don't pay enough attention to drug side effects. There are few to no studies done after drug approval, the data collected by the FDA on side effects of drugs is totally anecdotal and random. Doctors leave patients on drugs unless they rant and rave because they have no other choices in "accepted medical practice".
Alternative therapies are not given enough attention in the U.S. and they aren't covered by Medicare or insurance. This is another thing that needs to change.
In Edit- I just decided to go off of the primidone.
Phenobarbital and primidone
Some studies report few cognitive adverse effects (CAEs) with the use of phenobarbital [Wang et al. 2006]. However, studies involving children with epilepsy have linked this agent to lower IQ [Farwell et al. 1990; Camfield et al. 1979], and discontinuation of the drug can improve total IQ (mainly affecting nonverbal items) in children [Tonekaboni et al. 2006]. Phenobarbital is considered to have worse cognitive effects than valproate or carbamazepine [Calandre et al. 1990; Vining et al. 1987]. When compared with carbamazepine, primidone has been found to cause more adverse effects on motor performance and attention/concentration tests [Smith et al. 1987; Rodin et al. 1976]. One study reported attentional and memory difficulties in children [Riva and Devoti, 1996], but these effects were reversible after discontinuation. Another study [Manni et al. 1993] showed that when compared with controls, patients taking phenobarbital showed longer movement times, impaired attention and reduced processing speed, but no relationship was found with drug concentration.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229254/
Recent AVXL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM

